

Amendment

In the specification

Please replace the paragraph at page 4, lines 1-8, with the following paragraph.

By "HLA-binding" peptide we mean a peptide which binds to one or more HLA molecules. Typically, a peptide will show HLA binding in a T2 binding assay when present in a concentration range of 10 µM to 1 nM. Whether or not a peptide of human CD45 is an HLA-binding peptide can be determined using methods known in the art. These methods include the T2 HLA stabilisation assay described in Figure 1 Figures 1A and 1B, and the method described by Elvin *et al* (1993) *J. Immunol. Methods* **158**, 161-171.

Please replace the paragraph at page 31, lines 4-9, with the following paragraph.

Figure 1 shows Figures 1A and 1B show the result of an assay to measure HLA-A0201 binding of peptides. Peptide binding was measured using the T2 assay that is based on the ability of peptides to stabilise HLA-A0201 expression in the TAP-deficient T2 cells. The peptide 1218 (FLYDVIAST, SEQ ID NO:1) was one of the best binders and was used to stimulate CTL responses (see Figure 2).

Please replace the paragraph at page 32, lines 15-17, with the following paragraph.

Sixteen peptides of the CD45 molecule were selected and 14 of them we tested in HLA-A0201 binding assays as described in the legend to Figure 1 legends to Figures 1A and 1B. Twelve of the peptides showed binding activity (see Figure 1 Figures 1A and 1B).

U.S.S.N.: 10/003,983
Filed: October 31, 2001
TRANSMITTAL OF FORMAL DRAWINGS

The specification has been amended to conform the specification to the formal drawings as filed. No new matter has been added.

Respectfully submitted,



Tiffany B. Salmon
Reg. No. 55,589

Date: December 3, 2004

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2153 (Telephone)
(404) 879-2160 (Fax)